VerifiedBiotechnology Research

Glycomine Inc

Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

7-day free trial · no credit card

San Carlos, United States27(1 to 10)$1M to <$10Mglycomine.com LinkedIn

Verified contacts

available on Kipplo

LinkedIn employees

1 to 10 range

Open roles

—

no listings

Distinct roles

indexed titles

Tech stack

tools in use

Monthly traffic

180

organic / mo

Free for 7 days · 50 credits · no card · only pay for verified records.

Decision-makers and verified team members

16 contacts with verified email or phone · masked until revealed.

Showing 9 of 16 verified contacts

Top roles at Glycomine Inc

13 distinct titles indexed · top 10 shown.

2chief of staff, director of corporate development & strategy
1board member
1board observer
1chief technology officer
1director clinical operations
1patient advocate
1senior director of process development
1senior legal consultant
1senior scientitst
1sr director of product development
+3more titles

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up to reveal 16 verified contacts at Glycomine Inc

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.